Moderna, Inc.
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Non-cash PP&E additions included in accounts payable by Quarter
Non-cash PP&E additions included in accounts payable and accrued liabilities ($M) ($M)
Moderna Non-cash PP&E additions included in accounts payable: $1M in Q2 2026, down 133.3% from a year earlier.
Where the Q2 2026 figure comes from
Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Supplemental Cash Flow Information.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-cash PP&E additions included in accounts payable and accrued liabilities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1 | -133.3% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 35 | -30.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 41 | +115.8% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | -5 | -37.5% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | -3 | -40.0% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 50 | -45.1% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 19 | -205.6% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | -8 | -118.6% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | -5 | -171.4% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 91 | -7.1% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | -18 | +125.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 43 | +38.7% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 7 | -146.7% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 98 | +53.1% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | -8 | -117.8% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 31 | +47.6% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | -15 | -162.5% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 64 | +204.8% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 45 | +800.0% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 21 | +425.0% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 24 | +1,100.0% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2021 | Mar 31, 2021 | 21 | +200.0% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 5 | +61.3% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2020 | Sep 30, 2020 | 4 | -195.2% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 2 | -124.7% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 7 | -50.4% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 3.10 | +3,000.0% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | -4.20 | -72.7% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | -8.10 | +2,600.0% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 14.1 | -50.5% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 0.10 | – | Form 10-K (filed 2021-02-26) ↗ |
| Q3 2018 | Sep 30, 2018 | -15.4 | – | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | -0.30 | – | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2018 | Mar 31, 2018 | 28.5 | – | Form 10-Q (filed 2019-05-09) ↗ |
Cite this data
StockData. (2026). Moderna Non-cash PP&E additions included in accounts payable ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/capex-accrued-xbrl
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.